Pharmacological modulation of β-adrenoceptor function is one of the critical issues in the
treatment of patients with concurrent chronic obstructive pulmonary disease (COPD) and …

Pulmonary function can be reduced by [beta]-blockers. It has been established that no [beta]-
blocker is entirely safe in patients with chronic obstructive lung disease. An alternative …

The common coexistence of chronic obstructive pulmonary disease (COPD) and
cardiovascular disease (CVD) presents several therapeutic constraints that have not been …

Chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD) often coexist
and present clinicians with diagnostic and therapeutic challenges. Beta-blockers are a …

Review is devoted to the place of β-adrenoblockers in the treatment of cardiovascular
disease (CVD) in patients with chronic obstructive pulmonary disease (COPD). Currently, it …

Abstract β-Blockers are competitive antagonists at β-adrenergic receptors (β-AR) and are a
life-saving form of treatment in different cardiovascular diseases (CVD). Despite current …

Beta-blocker therapy has a mortality benefit in patients with hypertension, heart failure and
coronary artery disease, as well as during the perioperative period. These drugs have …

Beta-adrenergic blocking agents, or beta-blockers, are indicated in the management of
angina pectoris, myocardial infarction, hypertension, congestive heart failure (CHF), cardiac …

Patients with chronic heart failure (CHF) have a resting restrictive ventilatory defect. Any type
of exercise requires patients with CHF to markedly increase their minute ventilation. Patients …

Objectives: The purpose of this study was to determine the respiratory, hemodynamic, and
clinical effects of switching between β1-selective and nonselective beta-blockers in patients …